Takeda (NYSE: TAK) CEO Christophe Weber details Form 3 share and award holdings
Rhea-AI Filing Summary
Takeda Pharmaceutical’s President and CEO Christophe Weber has reported his initial ownership position on a Form 3. The filing lists direct holdings of 935,300 Ordinary Shares and 253,433 American Depositary Shares, plus various equity-based awards tied to future vesting dates.
The position includes 96,000 restricted stock units (RSUs) linked to Ordinary Shares, vesting on June 1, 2026 (46,100 shares), June 1, 2027 (32,700 shares) and June 1, 2028 (17,200 shares. It also includes 204,008 RSUs linked to American Depositary Shares, vesting on July 1, 2026 (95,744 shares), July 1, 2027 (72,384 shares) and July 1, 2028 (35,850 shares).
Weber also holds Tax Obligation Awards that are economically equivalent to Ordinary Shares, with underlying amounts of 46,367, 32,966 and 17,296 Ordinary Shares, expiring on June 1, 2026, June 1, 2027 and June 1, 2028. Upon vesting, these Tax Obligation Awards convert into cash payments primarily to cover tax obligations based on the then-current Ordinary Share price.
Positive
- None.
Negative
- None.
FAQ
What does Takeda (TAK) CEO Christophe Weber report on this Form 3?
How many restricted stock units on Ordinary Shares does Takeda (TAK) CEO hold?
What RSUs linked to American Depositary Shares does Takeda (TAK) disclose for its CEO?
What are the Tax Obligation Awards reported by Takeda (TAK) CEO Christophe Weber?
Does this Takeda (TAK) Form 3 show any insider share purchases or sales?
What is the significance of this Takeda (TAK) Form 3 for investors?